Navigation Links
Co-sponsors highlight important research to be presented at the 2013 Breast Cancer Symposium
Date:9/6/2013

SAN FRANSISCO, CA Five additional studies of note are among those that will be presented at the 2013 Breast Cancer Symposium, taking place September 7-9, 2013 at the San Francisco Marriott Marquis in San Francisco, California. Two studies examine cognitive function in women who undergo treatment for early-stage breast cancer; a third evaluates impact of tumor genotyping on clinical trial enrollment; and the final two evaluate the outcomes of different treatment approaches.

Saturday, September 7 Presentations

Abstract #48:
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.

General Poster Session A
Saturday, September 7, 2013, 11:30 AM 1:00 PM PST
Saturday, September 7, 2013, 4:30 PM 6:00 PM PST
Golden Gate Hall

Napa Parinyanitikul, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Abstract # 55:
Ten-year outcomes of accelerated partial breast irradiation compared with whole breast irradiation: A matched-pair analysis.

Poster Discussion A
Saturday, September 7, 2013, 4:00 PM 4:20 PM PST
Yerba Buena Ballroom, Salon 8

Jessica Wobb, MD
Oakland University William Beaumont School of
Medicine, Beaumont Cancer Institute
Royal Oak, MI

Sunday, September 8 Presentations

Abstract # 105:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Lara Heflin, PhD
New Mexico Highlands University
Las Vegas, NM

Abstract # 104:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Abstract # 145:
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.

Poster Discussion B
Sunday, September 8, 2013, 4:00 PM 4:20 PM PST
Yerba Buena Ballroom, Salon 8

Aditya Bardia, MD
Massachusetts General Hospital,
Harvard Medical School
Boston, MA


'/>"/>

Contact: Kate Blackburn
Kate.Blackburn@asco.org
571-483-1379
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. PhUSE Co-sponsors the Annual FDA/PhUSE Computational Science Symposium, in Silver Spring Maryland, USA, March 18th-19th 2013
2. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
3. Scientific session and new research highlights
4. Triple negative breast cancer symposium highlights current advances
5. Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment
6. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
7. New influenza virus from seals highlights the risks of pandemic flu from animals
8. JAAOS study highlights success of nerve transfer surgery
9. Researchers highlight treatment, research needs for homeless families
10. Deadly outbreak of West Nile virus highlights urgent need for more research, funding
11. AAO-HNSF 2012 new oral research daily highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: